Peter B. Gilbert
Ph.D., University of Washington, Biostatistics, 1996.
M.S., University of Washington, Biostatistics, 1994.
B.S., University of Washington, Mathematics, 1992.
Clinical trials for HIV vaccines.
Statistical methods in the areas of survival analysis, genetic sequence analysis, surrogate endpoints, causal inference.
For my complete CV including publications go to http://faculty.washington.edu/peterg
American Statistical Association
International Biometrics Society
Honors and Awards
2010, MERIT Award (R37) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, for the grant, “Statistical Methods in HIV Vaccine Efficacy Trials”
2005-2006, Ross L. Prentice Professorship, University of Washington, Department of Biostatistics
2000-2001, Excellent Teaching Rating, Harvard School of Public Health
1996, Senior Biostatistics Student Award, University of Washington
1995, Outstanding Student Scholarship, University of Washington, School of Public Health and Community Medicine
1994, Honorary Donovan J. Thompson Award, University of Washington, Outstanding Performance as Student in Biostatistics
1992, Phi Beta Kappa, University of Washington
1992, National Honor Society, Golden Key
1992, B.S., Magna Cum Laude, University of Washington
1988-1992, Dean's List, University of Washington
2005-2006, Deputy Director of Statistical Sciences, Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
2004-2008, Research Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
2002-2004, Research Assistant Professor, University of Washington, School of Public Health and Community Medicine, Department of Biostatistics
2002-2007, Associate Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
2001-2002, Assistant Member, Fred Hutchinson Cancer Research Center
1997, Research Fellow, Harvard University, School of Public Health
1997-2001, Assistant Professor, Harvard University, School of Public Health, Biostatistics
1995-1996, Graduate Research Assistant, University of Washington, HIVNET
Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.. Journal of the Royal Statistical Society. Series C, Applied statistics. 64(1):49-73.. 2015.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.. PLoS computational biology. 11(2):e1003973.. 2015.
Nonparametric Bounds and Sensitivity Analysis of Treatment Effects.. Statistical science : a review journal of the Institute of Mathematical Statistics. 29(4):596-618.. 2014.
Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.. Journal of virology.. 2014.
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination.. Science translational medicine. 6(228):228ra39.. 2014.
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine.. 2013.
Sieve analysis in HIV-1 vaccine efficacy trials.. Current opinion in HIV and AIDS.. 2013.
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.. Proceedings of the National Academy of Sciences of the United States of America. 110(22):9019-24.. 2013.
Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials.. Journal of the American Statistical Association. 108(503). 2013.
Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.. Biostatistics (Oxford, England). 14(1):60-74.. 2013.
Estimating the Efficacy of Preexposure Prophylaxis for HIV Prevention Among Participants With a Threshold Level of Drug Concentration.. American journal of epidemiology. 177(3):256-63.. 2013.
Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.. Biostatistics (Oxford, England).. 2013.
Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection.. The Journal of infectious diseases.. 2013.
Quantile regression for competing risks data with missing cause of failure. Statistica Sinica. 22(2). 2012.
Assessing Treatment-Selection Markers using a Potential Outcomes Framework.. Biometrics. 68(3):687-696.. 2012.